MedTrace Logo

PROTECT Continued Access Post Marketing Surveillance Trial

NCT00846846 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1018

Last updated 2015-05-04

Study results available
· View outcomes & findings →

Summary

In order to expand safety information in patients treated with the Endeavor Drug Eluting Stent System, or next generation model, a Continued Access (CA) study is added to the PROTECT Trial. The amended study is "PROTECT CONTINUED ACCESS" ("PROTECT CA").

Conditions

  • Coronary Artery Disease, Autosomal Dominant, 1

Interventions

DEVICE

Endeavor® Zotarolimus Eluting Coronary Stent System

Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation

Sponsors & Collaborators

  • Medtronic Vascular

    lead INDUSTRY

Principal Investigators

  • Lisa Bousquette · Medtronic Cardiovascular

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846846 on ClinicalTrials.gov